Skip to main content
. 2013 Sep;57(9):4172–4180. doi: 10.1128/AAC.00513-13

Table 7.

Susceptibility of ENF-resistant virus and clinical envelopes to BMS-626529 determined by the PhenoSense Entry assaya

Resistant envelope FC-IC50
BMS-626529 Enfuvirtide
1 2.9 30–100
5 0.17 30–100
8 0.32 30–100
10 0.18 >100
14 0.49 >100
a

FC-IC50, fold change in IC50 compared with control envelope. Mean values of two independent experiments are shown.